Novartis withdraws label extension bid for Alzheimer's drugs on CHMP 'concerns'
This article was originally published in Scrip
Executive Summary
Novartis has withdrawn its label extension application, submitted to the EMA's Committee for Medicinal Products for Human Use (CHMP), for medicines Exelon (rivastigmine) and Prometax (rivastigmine). The firm had been seeking marketing approval for the transdermal patch forms of the medicines as treatments for severe Alzheimer's dementia.